{"title":"艾滋病合并马尔尼菲塔芳菌病感染的临床特点及预后:一项单中心回顾性研究。","authors":"Zhangyan Weng, Yijie Lin, Wenliang Dai, Yijuan Zheng, Huatang Zhang, Minghui Zheng, Haoyi He, Youzhi Hong, Dawu Zeng, Zhijun Su, Xueping Yu","doi":"10.1007/s40121-025-01198-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The objective of the study was to determine the clinical features and prognostic risk factors of acquired immunodeficiency syndrome (AIDS) combined with Talaromyces marneffei (TM) infection.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical data of 133 hospitalized patients diagnosed with AIDS and TM co-infection. Patients were divided into an improvement group and a deterioration group on the basis of their discharge outcomes. To further investigate the severity of adverse outcomes, subgroup analysis was performed on the deterioration group. Due to the issue of complete separation in the data, Firth's logistic regression model was employed to identify independent prognostic factors. Finally, the predictive performance of the model was evaluated using the receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>Among 133 patients with AIDS and TM co-infection, the main manifestations were fever (93.23%) and severe immunodeficiency with median CD4<sup>+</sup> T cell count of 8.50 cells/μL, with blood culture showing the highest positive rate (93.85%). Firth's logistic regression analysis revealed that timely antifungal therapy (OR 0.004, 95% CI <0.001-0.047, P < 0.001) and higher baseline albumin (ALB) levels (OR 0.858, 95% CI 0.732-0.973, P = 0.016) were independent protective factors for improving patient prognosis. The area under the receiver operating characteristic (ROC) curve (AUC) of the model was 0.930 (95% CI 0.878-0.982).</p><p><strong>Conclusions: </strong>Timely antifungal therapy and good nutritional status are key determinants of prognosis in patients with AIDS and TM co-infection. Early diagnosis, prompt initiation of effective treatment, and active nutritional support are of great significance for improving patient survival outcomes.</p>","PeriodicalId":13592,"journal":{"name":"Infectious Diseases and Therapy","volume":" ","pages":"1935-1952"},"PeriodicalIF":5.3000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339780/pdf/","citationCount":"0","resultStr":"{\"title\":\"Clinical Characteristics and Prognosis of AIDS Complicated with Talaromycosis marneffei Infection: a Single-Center Retrospective Study.\",\"authors\":\"Zhangyan Weng, Yijie Lin, Wenliang Dai, Yijuan Zheng, Huatang Zhang, Minghui Zheng, Haoyi He, Youzhi Hong, Dawu Zeng, Zhijun Su, Xueping Yu\",\"doi\":\"10.1007/s40121-025-01198-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The objective of the study was to determine the clinical features and prognostic risk factors of acquired immunodeficiency syndrome (AIDS) combined with Talaromyces marneffei (TM) infection.</p><p><strong>Methods: </strong>We retrospectively analyzed the clinical data of 133 hospitalized patients diagnosed with AIDS and TM co-infection. Patients were divided into an improvement group and a deterioration group on the basis of their discharge outcomes. To further investigate the severity of adverse outcomes, subgroup analysis was performed on the deterioration group. Due to the issue of complete separation in the data, Firth's logistic regression model was employed to identify independent prognostic factors. Finally, the predictive performance of the model was evaluated using the receiver operating characteristic (ROC) curve.</p><p><strong>Results: </strong>Among 133 patients with AIDS and TM co-infection, the main manifestations were fever (93.23%) and severe immunodeficiency with median CD4<sup>+</sup> T cell count of 8.50 cells/μL, with blood culture showing the highest positive rate (93.85%). Firth's logistic regression analysis revealed that timely antifungal therapy (OR 0.004, 95% CI <0.001-0.047, P < 0.001) and higher baseline albumin (ALB) levels (OR 0.858, 95% CI 0.732-0.973, P = 0.016) were independent protective factors for improving patient prognosis. The area under the receiver operating characteristic (ROC) curve (AUC) of the model was 0.930 (95% CI 0.878-0.982).</p><p><strong>Conclusions: </strong>Timely antifungal therapy and good nutritional status are key determinants of prognosis in patients with AIDS and TM co-infection. Early diagnosis, prompt initiation of effective treatment, and active nutritional support are of great significance for improving patient survival outcomes.</p>\",\"PeriodicalId\":13592,\"journal\":{\"name\":\"Infectious Diseases and Therapy\",\"volume\":\" \",\"pages\":\"1935-1952\"},\"PeriodicalIF\":5.3000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339780/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious Diseases and Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s40121-025-01198-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious Diseases and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40121-025-01198-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/23 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
Clinical Characteristics and Prognosis of AIDS Complicated with Talaromycosis marneffei Infection: a Single-Center Retrospective Study.
Introduction: The objective of the study was to determine the clinical features and prognostic risk factors of acquired immunodeficiency syndrome (AIDS) combined with Talaromyces marneffei (TM) infection.
Methods: We retrospectively analyzed the clinical data of 133 hospitalized patients diagnosed with AIDS and TM co-infection. Patients were divided into an improvement group and a deterioration group on the basis of their discharge outcomes. To further investigate the severity of adverse outcomes, subgroup analysis was performed on the deterioration group. Due to the issue of complete separation in the data, Firth's logistic regression model was employed to identify independent prognostic factors. Finally, the predictive performance of the model was evaluated using the receiver operating characteristic (ROC) curve.
Results: Among 133 patients with AIDS and TM co-infection, the main manifestations were fever (93.23%) and severe immunodeficiency with median CD4+ T cell count of 8.50 cells/μL, with blood culture showing the highest positive rate (93.85%). Firth's logistic regression analysis revealed that timely antifungal therapy (OR 0.004, 95% CI <0.001-0.047, P < 0.001) and higher baseline albumin (ALB) levels (OR 0.858, 95% CI 0.732-0.973, P = 0.016) were independent protective factors for improving patient prognosis. The area under the receiver operating characteristic (ROC) curve (AUC) of the model was 0.930 (95% CI 0.878-0.982).
Conclusions: Timely antifungal therapy and good nutritional status are key determinants of prognosis in patients with AIDS and TM co-infection. Early diagnosis, prompt initiation of effective treatment, and active nutritional support are of great significance for improving patient survival outcomes.
期刊介绍:
Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.